Arvinas, Inc. (ARVN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 26 | 54 | 131 | 79 | 263 | 263 | 317 | 296 |
| Operating profit | $m | -115 | - | ||||||
| Net profit | $m | -119 | -191 | -282 | -367 | -199 | -81 | - | -11 |
| EPS reported | $ | -1.28 | 0.14 | ||||||
| Operating cashflow per share | $ | -4.22 | -3.19 | ||||||
| Capex per share | $ | 0.03 | 0.03 | ||||||
| FCF per share | $ | -4.25 | -3.22 | ||||||
| Free cash flow | $m | -276 | -209 | ||||||
| Net debt | $m | -685 | -567 | ||||||
| Book value equity | $m | 434 | 562 | ||||||
| Book value per share | $ | 6.68 | 8.56 | ||||||
| Number of shares | m | 64.9 | 65.7 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 46.94 | ||||||
| P/B LTM | x | 1.77 | 1.37 | ||||||
| P/S LTM | x | 2.93 | 2.43 | ||||||
| P/FCF LTM | x | -2.79 | -3.69 | ||||||
| EV/EBITDA LTM | x | -8.44 | 219.21 | ||||||
| EV/Sales LTM | x | 2.42 | 1.64 | ||||||
| Earnings Yield LTM | % | -10.50% | +2.13% | ||||||
| FCF Yield | % | -35.82% | -27.13% | ||||||
| Quality | |||||||||
| ROE | % | -18.63% | +1.91% | ||||||
| ROIC | % | -19.91% | -2.18% | ||||||
| Operating margin | % | -43.75% | -4.45% | ||||||
| Gross margin | % | +98.02% | +96.43% | ||||||
| FCF/Sales | % | -104.99% | -65.93% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -0.30% | +20.24% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -30.98 | -25.46 | ||||||
| Net Debt/EBITDA | x | 1.78 | -29.69 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.05% | +0.08% | ||||||
| Net debt/Equity | x | -1.58 | -1.01 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free